GSK Says Teva's Skinny-Label Row Is 'No Threat' To Generics
Teva Pharmaceuticals' "doomsday scenario" that upholding a $235 million infringement verdict against it would destroy a practice that gets generic drugs on the market sooner doesn't hold up when the facts...To view the full article, register now.
Already a subscriber? Click here to view full article